TRIB3 and non-small cell lung carcinoma: Additionally, EGFR strongly correlates with NSCLC progression and drug resistance, while TRIB3 boosts EGFR stability, so inhibits the TRIB3-EGFR interaction to degrade EGFR, eventually decelerating NSCLC progression [174].